Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection

다국어 초록 (Multilingual Abstract)

We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who wereadmitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receivedarunavir-cobicistat (800–150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 receivedother antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and thecrude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95%confidence interval (CI) 0.04–0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistatgroup, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortalitythan the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associatedwith a significant survival benefit in critically ill patients with SARS-CoV-2 infection.

참고문헌 (Reference)

1 Chu CM, "Role of lopinavir/ritonavir in the treatment of SARS : initial virological and clinical findings" 59 : 252-256, 2004

2 Curran A, "Rezolsta®(darunavir/cobicistat) : first boosted protease inhibitor co-formulated with cobicistat" 17 : 114-120, 2015

3 Putcharoen O, "Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS" 9 : 5763-5769, 2015

4 James M. Sanders, "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)" American Medical Association (AMA) 2020

5 Dong L, "Discovering drugs to treat coronavirus disease 2019(COVID-19)" 14 : 58-60, 2020

6 Zanon D, "Data on the stability of darunavir/cobicistat suspension after tablet manipulation" 30 : 105552-, 2020

7 China News Network, "Abidol and darunavir can effectively inhibit coronavirus"

8 Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19" 382 : 1787-1799, 2020